11 min listen
Healthcare: 3 Beaten-Up Biotechs -- Are They Buys?
FromIndustry Focus
ratings:
Length:
31 minutes
Released:
Oct 9, 2019
Format:
Podcast episode
Description
Here's why post-approval setbacks have caused Puma Biotechnology, Clovis Oncology, and Regenxbio shares to tumble, and if any of these stocks are finally worth buying. Stocks: PBYI, CLVS, RGNX Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter
Released:
Oct 9, 2019
Format:
Podcast episode
Titles in the series (100)
Energy: What Wall Street Got Wrong This Week by Industry Focus